About the PMPRB

The PMPRB protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

Meds Entry Watch, 2017

Meds Entry Watch, 2017

Most new medicines approved in 2016 and 2017 came with high treatment costs.

Find out more…

CompassRx 4

Market Intelligence Report: Anti-VEGF Drugs for Retinal Conditions, 2017

Spending on this drug class grew by 16.7% in 2017 and stands at just under $700 million.

Find out more…

CompassRx 4

CompassRx 2016/17

The most recent edition of the Patented Medicine Prices Review Board’s (PMPRB) CompassRx report found that public drug plan expenditures increased by an additional 1.9% in 2016-17.

Find out more…

SteeringCommittee

The PMPRB is consulting with its stakeholders on changes to its non-binding guidelines (the “Guidelines”), as contemplated by subsection 96(4) of the Patent Act.

Find out more

PMPRB Guidelines Scoping Paper

The PMPRB today published a scoping paper which provides its initial thoughts on how best to operationalize the Minister of Health’s proposed amendments to the Patented Medicines Regulations, which were published in the Canada Gazette, Part I on December 2, 2017.

Find out more…

I am a/an...

Consumer

Patentee

Other Stakeholder

Features

Annual Report 2017

Annual Report

PMPRB NEWSletter

Analytical Studies

Date modified: